Active	Status	Sponsor type	Region	Phase	Filter
12 Active 0 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lombardi, Giuseppe
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
SONOBIRD, NCT05902169: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM	Recruiting	3	560	Europe, US	SonoCloud-9 (SC9), Carboplatin, CycloButane DiCarboxylic Acid (CBDCA), Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Temozolomide, Temodal	CarThera	Glioblastoma, Recurrent Glioblastoma, GBM	01/28	06/28
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25
RACTAC, NCT04224441: Repurposing Chlorpromazine in the Treatment of Glioblastoma	Recruiting	2	41	Europe	Chlorpromazine Pill, Temozolomide	Marco G Paggi, MD, PhD, Regina Elena Cancer Institute, Carlo Besta Neurological Institute, Istituto Oncologico Veneto IRCCS	Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma	06/22	12/22
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Jan 2023 - Jun 2023 : Data from trial for glioblastoma Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults	Active, not recruiting	2	210	Europe, US	Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine	CNS Pharmaceuticals, Inc., Worldwide Clinical Trials	Glioblastoma Multiforme, Adult	12/24	03/25
MIRAGE, NCT06275919: Regorafenib for Recurrent Grade 2 and 3 Meningioma ( Trial)	Recruiting	2	104	Europe	Regorafenib 40 MG Oral Tablet, Local Standard of Care	Istituto Oncologico Veneto IRCCS, Bayer	Meningioma, Malignant	12/26	03/27
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Recruiting	2	45	Europe, Japan, US, RoW	Abemaciclib, LY2835219, Temozolomide	Eli Lilly and Company	Glioma	07/27	02/28
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression	Recruiting	1/2	142	Europe	L19TNF, onfekafusp alfa, Lomustine	Philogen S.p.A.	Glioblastoma	03/25	12/25
REGOMA-2, NCT06095375: Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients	Active, not recruiting	1	36	Europe	Regorafenib, Temozolomide	Istituto Oncologico Veneto IRCCS, Bayer S.p.A	Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma	10/24	12/25
GLIO-AI, NCT06620055: Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas	Recruiting	N/A	164	Europe		Centro di Riferimento Oncologico - Aviano	Glioma	11/28	11/28
SOPRANO, NCT05630664: Liquid Biopsy in High-grade Gliomas and Meningiomas	Recruiting	N/A	90	Europe		IRCCS San Raffaele, Alleanza Contro il Cancro	High Grade Glioma, High Grade Meningioma	09/25	09/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access	Recruiting	N/A	4975	Europe, RoW	RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon	European Organisation for Research and Treatment of Cancer - EORTC	All Tumor Types	03/26	03/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lombardi, Giuseppe
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study) Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma	Recruiting	3	450	Europe, Canada, Japan, US, RoW	Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo	Chimerix	H3 K27M, Glioma	08/26	08/26
SONOBIRD, NCT05902169: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM	Recruiting	3	560	Europe, US	SonoCloud-9 (SC9), Carboplatin, CycloButane DiCarboxylic Acid (CBDCA), Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Temozolomide, Temodal	CarThera	Glioblastoma, Recurrent Glioblastoma, GBM	01/28	06/28
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25
RACTAC, NCT04224441: Repurposing Chlorpromazine in the Treatment of Glioblastoma	Recruiting	2	41	Europe	Chlorpromazine Pill, Temozolomide	Marco G Paggi, MD, PhD, Regina Elena Cancer Institute, Carlo Besta Neurological Institute, Istituto Oncologico Veneto IRCCS	Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma	06/22	12/22
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Jan 2023 - Jun 2023 : Data from trial for glioblastoma Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults	Active, not recruiting	2	210	Europe, US	Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine	CNS Pharmaceuticals, Inc., Worldwide Clinical Trials	Glioblastoma Multiforme, Adult	12/24	03/25
MIRAGE, NCT06275919: Regorafenib for Recurrent Grade 2 and 3 Meningioma ( Trial)	Recruiting	2	104	Europe	Regorafenib 40 MG Oral Tablet, Local Standard of Care	Istituto Oncologico Veneto IRCCS, Bayer	Meningioma, Malignant	12/26	03/27
NCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy	Recruiting	2	45	Europe, Japan, US, RoW	Abemaciclib, LY2835219, Temozolomide	Eli Lilly and Company	Glioma	07/27	02/28
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression	Recruiting	1/2	142	Europe	L19TNF, onfekafusp alfa, Lomustine	Philogen S.p.A.	Glioblastoma	03/25	12/25
REGOMA-2, NCT06095375: Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients	Active, not recruiting	1	36	Europe	Regorafenib, Temozolomide	Istituto Oncologico Veneto IRCCS, Bayer S.p.A	Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma	10/24	12/25
GLIO-AI, NCT06620055: Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas	Recruiting	N/A	164	Europe		Centro di Riferimento Oncologico - Aviano	Glioma	11/28	11/28
SOPRANO, NCT05630664: Liquid Biopsy in High-grade Gliomas and Meningiomas	Recruiting	N/A	90	Europe		IRCCS San Raffaele, Alleanza Contro il Cancro	High Grade Glioma, High Grade Meningioma	09/25	09/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access	Recruiting	N/A	4975	Europe, RoW	RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon	European Organisation for Research and Treatment of Cancer - EORTC	All Tumor Types	03/26	03/26